Ronconi Giulia, Dondi Letizia, Calabria Silvia, Piccinni Carlo, Pedrini Antonella, Dondi Leonardo, Dell'Anno Irene, Esposito Immacolata, Addesi Alice, Viale Pierluigi, Martini Nello
Fondazione Ricerca e Salute (ReS), Roma.
Drugs & Health Srl, Roma.
Recenti Prog Med. 2023 Apr;118(4):204-221. doi: 10.1701/4009.39888.
The community-acquired pneumonia (Cap) and the acute exacerbation of chronic obstructive pulmonary disease (Aecopd) frequently receive wrong therapies, leading to the increase of healthcare consumption resources, direct and indirect costs, and antimicrobial resistance. This study identified Cap and Aecopd hospitalized events, and analyzed them in terms of comorbidities, antibiotic use, re-hospitalizations, diagnostics and costs, from the perspective of the Italian national health service (Inhs).
From the database of Fondazione Ricerca e Salute (ReS), hospitalizations for Cap and Aecopd from 2016 to 2019. Demographics, comorbidities and mean in-hospital stay at the baseline, antibiotics reimbursed by the Inhs within 15 days before and after the index event, outpatient diagnostics performed before the event and in-hospital diagnostics, and direct costs charged to the Inhs, are assessed.
From 2016 to 2019 (~5 million inhabitants/year), 31,355 events of Cap (1.7x1000/year) and 42,489 events of Aecopd (4.3x1000 inhabitants aged ≥45/year) were identified, of which 32% and 26.5%, respectively, were treated with antibiotics before the hospitalization. The highest frequency of hospitalizations and comorbidities, and the longest mean in-hospital stays are found among elderly. Events not treated before and after the hospitalization showed the longest in-hospital stay. More than 12 Ddd (defined daily dose) are dispensed after the discharge. Local outpatient diagnostics are performed before the admission to <1% of the events; in-hospital diagnostics are registered in 5.6% and 1.2% of Cap and Aecopd, respectively, discharge forms. About 8% and 24% of Cap and Aecopd, respectively, are re-hospitalized during one subsequent year, mainly within one month. The mean expenditures per event of Cap and Aecopd were € 3646 and € 4424, respectively: hospitalizations, antibiotics and diagnostics accounted for the 99%, 1% and <0.1% of the total expense, respectively.
This study provided a very high dispensation of antibiotics after the hospitalization for Cap and Aecopd, while a very low use of differential diagnostics available within the observed periods, to the detriment of the enforcement actions proposed at institutional levels.
社区获得性肺炎(Cap)和慢性阻塞性肺疾病急性加重(Aecopd)经常接受错误的治疗,导致医疗消费资源、直接和间接成本增加以及抗菌药物耐药性上升。本研究从意大利国家卫生服务(Inhs)的角度识别了Cap和Aecopd住院事件,并从合并症、抗生素使用、再次住院、诊断和成本方面进行了分析。
从Fondazione Ricerca e Salute(ReS)数据库中获取2016年至2019年Cap和Aecopd的住院数据。评估人口统计学、合并症以及基线时的平均住院时间、指数事件前后15天内Inhs报销的抗生素、事件前进行的门诊诊断和住院诊断,以及向Inhs收取的直接成本。
2016年至2019年(每年约500万居民),共识别出31355例Cap事件(每年1.7×1000例)和42489例Aecopd事件(年龄≥45岁的居民每年4.3×1000例),其中分别有32%和26.5%在住院前接受了抗生素治疗。老年人的住院频率和合并症发生率最高,平均住院时间最长。住院前后未接受治疗的事件住院时间最长。出院后发放超过12个限定日剂量(Ddd)。入院前进行局部门诊诊断的事件不到1%;Cap和Aecopd的住院诊断分别在5.6%和1.2%的出院病例中记录。Cap和Aecopd分别约有8%和24%在随后一年内再次住院,主要在一个月内。Cap和Aecopd每例事件平均支出分别为3646欧元和4424欧元:住院、抗生素和诊断分别占总费用的99%、1%和<0.1%。
本研究表明,Cap和Aecopd住院后抗生素的使用量非常高,而在观察期内可获得的鉴别诊断使用量非常低,不利于机构层面提出的执法行动。